Zobrazeno 1 - 10
of 204
pro vyhledávání: ''
Autor:
Daniel L. Flynn, Jarnail Singh, Bryan D. Smith, César Serrano, Alfonso García-Valverde, Anu Gupta
Publikováno v:
Molecular Cancer Therapeutics. 20:1234-1245
The majority of gastrointestinal stromal tumors (GIST) harbor constitutively activating mutations in KIT tyrosine kinase. Imatinib, sunitinib, and regorafenib are available as first-, second-, and third-line targeted therapies, respectively, for meta
Autor:
Sung Chul Lim, Youngnam Cho, Y. J. Kim, Seungmin Kang, Kyu Min Kim, Moon-Chang Baek, Keon Wook Kang, Miso Park, Ju Hyun Bae, Sung Baek Jeong, Jin Ki Kim, Dae Won Jun, Yong June Choi, Seung-Hyun Lee, Jiwon Kim, Wankyu Kim, HyungJae Lee, Sung Yun Cho
Publikováno v:
Cancer Research. 81:3539-3553
Extracellular vesicles (EV) in the tumor microenvironment have emerged as crucial mediators that promote proliferation, metastasis, and chemoresistance. However, the role of circulating small EVs (csEV) in cancer progression remains poorly understood
Autor:
Eunice Y. Lau, Man Tong, Katherine Po Sin Chung, Terence K. Lee, Stephanie Ma, Rainbow Wing Hei Leung, Etienne H. Mok, Irene Oi-Lin Ng, Martina Mang Leng Lei, Q Zhao, Vincent W. Keng, Carmen Oi Ning Leung, Hoi Wing Leung, Cong Ma
Publikováno v:
Cancer Research. 81:3229-3240
The survival benefit derived from sorafenib treatment for patients with hepatocellular carcinoma (HCC) is modest due to acquired resistance. Targeting cancer stem cells (CSC) is a possible way to reverse drug resistance, however, inhibitors that spec
Autor:
Pelin Gülizar Ersan, Hong Pei, Joel Linden, Sara Serra, Kim Phan, Qiping Zhao, Caglar Cekic, Renee Clift, H. Michael Shepard, Lei Huang, Michael J. LaBarre, Mertkaya Aras, Christopher D. Thanos, Lin Wang, Ozgur Sahin, Jessica Cowell, Xiaoming Li, Silvia Deaglio, Luz Marina Londoño, Ozge Saatci
Publikováno v:
Cancer Research. 81:3319-3332
Extracellular adenosine in tumors can suppress immune responses and promote tumor growth. Adenosine deaminase 2 (ADA2) converts adenosine into inosine. The role of ADA2 in cancer and whether it can target adenosine for cancer therapy has not been inv
Autor:
Marcos Galán-Ganga, Alberto J. Schuhmacher, Paula Nogales, Fatima Al-Shahrour, Miguel Jiménez-Alcázar, Lucía Zhu, Javier Perales-Patón, Scott W. Lowe, Álvaro Curiel-García, Massimo Squatrito
Publikováno v:
Mol Cancer Ther
Glioblastoma (GBM) is the most frequent and aggressive primary tumor type in the central nervous system in adults. Resistance to chemotherapy remains one of the major obstacles in GBM treatment. Identifying and overcoming the mechanisms of therapy re
Autor:
Ki Hyun Yoo, Mi Hyeon Jang, Chang Hoon Cho, Alfredo Oliveros, Joseph A. Baur, Jason J. Tang, Mun Gyeong Bae, S. John Weroha, Jong Hoon Choi, Danielle Brogren, Xiaonan Hou, Mohammad Abdur Rashid, John R. Hawse, Ana Mia Corujo-Ramirez, Lindsey A Kirkeby
Publikováno v:
Cancer Res
Chemotherapy-induced cognitive impairment (CICI) is often reported as a neurotoxic side effect of chemotherapy. Although CICI has emerged as a significant medical problem, meaningful treatments are not currently available due to a lack of mechanistic
Autor:
Zhe Zhi, Lei Chen, Yiming Hu, Yongping Shao, Yan Wang, Yibo Ren, Jiankang Liu, Shujun Han, Yuwei Yan, Yan Zheng
Publikováno v:
Cancer Research. 81:2918-2929
The long noncoding RNA (lncRNA) SAMMSON is required for human melanoma cell growth and survival. However, whether SAMMSON regulates the response of mutant BRAF melanoma cells to RAF inhibitors remains unknown. In this work, we showed that SAMMSON is
Autor:
Ladislav Merta, Natalia Torrealba, Jaroslav Truksa, Jan Stursa, Jiri Neuzil, Lukas Werner, Daniel Rösel, Veronika Tomkova, Kristyna Blazkova, Jan Brábek, Sandra Lettlova, Sukanya Balkrishna Jadhav, Miroslava Kari Adamcová, Cristian Sandoval-Acuña
Publikováno v:
Cancer Research. 81:2289-2303
Deferoxamine (DFO) represents a widely used iron chelator for the treatment of iron overload. Here we describe the use of mitochondrially targeted deferoxamine (mitoDFO) as a novel approach to preferentially target cancer cells. The agent showed mark
Autor:
Krishanthan Vigneswaran, Shoeb Lallani, Renee Read, Nathaniel H. Boyd, Andrew B. Boucher, Se-Yeong Oh, Stewart G. Neill, Jeffrey J. Olson
Publikováno v:
Clin Cancer Res
Purpose: Glioblastomas (GBMs), neoplasms derived from glia and neuroglial progenitor cells, are the most common and lethal malignant primary brain tumors diagnosed in adults, with a median survival of 14 months. GBM tumorigenicity is often driven by
Autor:
Paul Zolkind, Gavin P. Dunn, Ann Marie Egloff, Erica K. Barnell, Ravindra Uppaluri, Obi L. Griffith, Tenny Mudianto, Tusar Giri, Rachel S. Riley, Malachi Griffith, Jason Webb, Zachary L. Skidmore, Douglas Adkins, Katie M. Campbell, Ibrahim Ozgenc
Publikováno v:
Clin Cancer Res
Purpose: In a head and neck squamous cell carcinoma (HNSCC) “window of opportunity” clinical trial, we reported that trametinib reduced MEK-Erk1/2 activation and resulted in tumor responses in a subset of patients. Here, we investigated resistanc